Immunosuppressive drug

Global Immunosuppressant Drugs Market (2020 to 2025) - Featuring Astellas Pharma, Sanofi (Genzyme) & Bristol-Myers Squibb Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 19, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Immunosuppressants, Clinical medicine, Transplantation medicine, Macrolides, RTT, Immunosuppressive drug, Organ transplantation, Tacrolimus, Ciclosporin

The "Immunosuppressant Drugs Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunosuppressant Drugs Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The Immunosuppressant Drugs Market is expected to register a CAGR of 4.6% during the forecast period.
  • Commonly used immunosuppressant drugs include tacrolimus, cyclosporine A, glucocorticoids, methotrexate, and rituximab.
  • In terms of market share, few of the major players are currently dominating the market.

Research Report on Organ Transplantation in China, 2020-2024 - Immunosuppressants Market Expected to Be Over CNY 30 Billion by 2024

Retrieved on: 
Friday, January 24, 2020
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Organ transplantation, Immunosuppression, Immunosuppressive drug, Kidney transplantation

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Research Report of Organ Transplantation in China 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Research Report of Organ Transplantation in China 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Although facing challenges, the annual number of organ transplantation is estimated to be more than 40 thousand according to this research, and the market of immunosuppressants is expected to be over CNY 30 billion by 2024.
  • The increasing number of organ transplants in China greatly expands the market of immunosuppressive drugs that organ transplant recipients need to take for life.
  • With wider clinical application of new immunosuppressant, the market size of immunosuppressants in China exceeded CNY 15 billion in 2018.

Global Heart Transplantation Therapeutics Market 2020-2024: AbbVie Inc, Mylan NV, Pfizer Inc & Teva Pharmaceutical Industries Ltd - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 15, 2020
Surgery, Health, Cardiology, Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Heart diseases, Immunosuppressive drug, Organ transplantation, Immunosuppression, Heart failure, Heart transplantation

Global Heart Transplantation Therapeutics Market: About this market

Key Points: 
  • Global Heart Transplantation Therapeutics Market: About this market
    The heart transplantation therapeutics market analysis considers sales from immunosuppressants and supplementary medications products.
  • Also, our global heart transplantation therapeutics market report looks at factors such as rising prevalence of cardiovascular diseases and heart failures, availability of drugs in multiple dosage forms, and high dependency of immunosuppressants for heart transplantation.
  • Thus, the high dependency on immunosuppressants for heart transplantation will lead to the expansion of the global heart transplantation therapeutics market at a CAGR of almost 3% during the forecast period.
  • The introduction of novel approaches for heart regeneration and transplantation is one of the key heart transplantation therapeutics market trends.

National Coalition of Kidney and Transplant Organizations celebrate Congress' Bipartisan Effort to Honor the Gift of Kidney Donation

Retrieved on: 
Monday, January 6, 2020
Medical specialties, Medicine, Clinical medicine, Organ transplantation, Transplantation medicine, Kidney transplantation, Medicare, Immunosuppressive drug, Lung transplantation

The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Actintroduced today in the House by Reps. Ron Kind (R-WI) and Michael Burgess, M.D.

Key Points: 
  • The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Actintroduced today in the House by Reps. Ron Kind (R-WI) and Michael Burgess, M.D.
  • (R-TX)would allow kidney transplant recipients to maintain Medicare Part B coverage for immunosuppressive medications beyond the current 3-year limit, extending coverage for the lifetime of the transplanted kidney.
  • Honor the Gift is a national patient-centered campaign focused on extending Medicare coverage of immunosuppressive medication for kidney transplant recipients beyond the current three-year limit.
  • The campaign is powered by a coalition of stakeholder groups from around the country dedicated to protecting kidney transplant patients and honoring the gift of kidney donation by providing civic engagement tools and resources.

Kidney Recipients May Get Much Needed Help -Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 Introduced In U.S. House of Representatives

Retrieved on: 
Monday, January 6, 2020
Medical specialties, Medicine, Clinical medicine, Kidney transplantation, Organ transplantation, Immunosuppressive drug, Medicare, Lung transplantation

5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.

Key Points: 
  • 5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.
  • AST and transplant community are grateful for our House champions' longtime support of transplant recipients, donors, and their families.
  • The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 would extend Medicare coverage of immunosuppressive drugs for kidney transplant recipients.
  • Dr. Blumberg applauds the House bill sponsors for their support of transplant patients and continuing efforts to address the immunosuppressive drug coverage issue.

National Kidney Foundation Applauds New Immunosuppressive Drug Coverage Legislation to Help Save Transplant Patients from Organ Rejection

Retrieved on: 
Monday, January 6, 2020
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Kidney transplantation, National Kidney Foundation, Transplant rejection, Organ transplantation, Immunosuppressive drug

NEW YORK, Jan. 6, 2020 /PRNewswire/ -- "New legislation introduced today to extend Medicare coverage of immunosuppressive drugs for kidney transplant patients will not only save lives but save taxpayers money.

Key Points: 
  • NEW YORK, Jan. 6, 2020 /PRNewswire/ -- "New legislation introduced today to extend Medicare coverage of immunosuppressive drugs for kidney transplant patients will not only save lives but save taxpayers money.
  • "When a patient receives a kidney transplant, the body knows that the new kidney is foreign and will attack the new kidney and try to damage or destroy it.
  • Taking life-saving immunosuppressive drugs suppresses the body's ability to do this and helps prevent organ rejection.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease.

The global heart transplantation therapeutics market at a CAGR of almost 3% during the forecast period

Retrieved on: 
Tuesday, December 31, 2019
Medical specialties, Medicine, Clinical medicine, Transplantation medicine, Heart diseases, Immunosuppressive drug, Immunosuppression, Organ transplantation, Heart transplantation, Heart failure

Global Heart Transplantation Therapeutics Market: About this market

Key Points: 
  • Global Heart Transplantation Therapeutics Market: About this market
    This heart transplantation therapeutics market analysis considers sales from immunosuppressants and supplementary medications products.
  • Also, our global heart transplantation therapeutics market report looks at factors such as rising prevalence of cardiovascular diseases and heart failures, availability of drugs in multiple dosage forms, and high dependency of immunosuppressants for heart transplantation.
  • However, adverse effects of immunosuppressants, demand-supply imbalance for organ transplantation, and long-term complications associated with heart transplantation may hamper the growth of the heart transplantation therapeutics industry over the forecast period.
  • Thus, the high dependency on immunosuppressants for heart transplantation will lead to the expansion of the global heart transplantation therapeutics market at a CAGR of almost 3% during the forecast period.

Global Heart Transplantation Therapeutics Market 2020-2024 | Evolving Opportunities with AbbVie Inc. and Mylan NV | Technavio

Retrieved on: 
Friday, December 13, 2019
Health, Surgery, Other Science, Pharmaceutical, Cardiology, Science, Medicine, Medical specialties, Clinical medicine, Medical emergencies, Pulmonary edema, Transplantation medicine, Edema, Organ transplantation, Immunosuppressive drug

High dependency on immunosuppressants for heart transplantation and the advent of advanced techniques for organ transplantation is anticipated to boost the growth of the market.

Key Points: 
  • High dependency on immunosuppressants for heart transplantation and the advent of advanced techniques for organ transplantation is anticipated to boost the growth of the market.
  • Thus, the high dependency on immunosuppressants for heart transplantation is expected to drive market growth during the forecast period.
  • Major Five Heart Transplantation Therapeutics Market Companies:
    AbbVie Inc. is headquartered in the US and operates under the business segment: Pharmaceutical products.
  • Pulmonary Edema Therapeutics Market Global Pulmonary Edema Therapeutics Market by geography (Asia, Europe, North America, and ROW), and type (cardiogenic pulmonary edema and non-cardiogenic pulmonary edema).

Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine

Retrieved on: 
Monday, December 2, 2019
Research, Publishing, Communications, Clinical trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Medicine, Medical specialties, Branches of biology, Interleukins, Immunosuppressive drug, Organ transplantation, Transplantation medicine, Placebo, Interleukin 6, Inflammation

Were encouraged that satralizumab may soon provide a new treatment option for people living with NMOSD.

Key Points: 
  • Were encouraged that satralizumab may soon provide a new treatment option for people living with NMOSD.
  • Satralizumab inhibits interleukin-6 (IL-6) signaling, which is believed to play a key role in the inflammation that occurs in people with NMOSD.
  • Overall, the proportion of patients with serious adverse events was similar between the satralizumab and placebo treatment groups.
  • Positive Phase III results for satralizumab, as both monotherapy and in combination with baseline immunosuppressant therapy, suggest that IL-6 inhibition may be an effective therapeutic approach for NMOSD.

Global Organ Transplantation Market Analysis & Forecast 2014-2019 & 2024 | by Product Type, Application, Region & Country - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Surgery, Health, Medical specialties, Medicine, Clinical medicine, Organ transplantation, Transplantation medicine, Immunosuppressive drug, Transplant, United Network for Organ Sharing, Intestine transplantation

The "Global Organ Transplantation Market: World Market Review By Product Type (Organ Preservation Products, Transplant Diagnostics, Immunosuppressant Drugs, Others), By Applications (Kidney, Liver, Heart, Others), By Region, By Country (2019 Edition): Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Organ Transplantation Market: World Market Review By Product Type (Organ Preservation Products, Transplant Diagnostics, Immunosuppressant Drugs, Others), By Applications (Kidney, Liver, Heart, Others), By Region, By Country (2019 Edition): Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
  • Immunosuppressant drugs hold Hanging dynamics of patient profiling during organ transplantation has been impelling the market growth of transplant diagnostics.
  • Further, hanging dynamics of patient profiling during organ transplantation has been impelling the market growth of transplant diagnostics.
  • Global Organ Transplantation Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)
    Organ Transplantation Market - Size, Growth, Forecast
    By Product Type - Organ Preservation Products, Transplant Diagnostics, Immunosuppressant Drugs, Others
    Regional Analysis - North America, Europe, APAC, ROW (Actual Period: 2017-2018, Forecast Period: 2019-2024)
    Organ Transplantation Market - Size, Growth, Forecast
    By Product Type - Organ Preservation Products, Transplant Diagnostics, Immunosuppressant Drugs, Others
    Organ Transplantation Market - Size, Growth, Forecast
    By Product Type - Organ Preservation Products, Transplant Diagnostics, Immunosuppressant Drugs, Others